Timothy J Whelan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2319772/publications.pdf

Version: 2024-02-01

29994 20,329 174 54 citations h-index papers

139 g-index 178 178 178 16134 docs citations times ranked citing authors all docs

10424

#	Article	IF	Citations
1	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2018, 379, 111-121.	13.9	1,558
2	Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. New England Journal of Medicine, 2010, 362, 513-520.	13.9	1,504
3	Tailoring therapiesâ€"improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
4	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2015, 373, 2005-2014.	13.9	1,146
5	Regional Nodal Irradiation in Early-Stage Breast Cancer. New England Journal of Medicine, 2015, 373, 307-316.	13.9	1,022
6	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. Journal of Clinical Oncology, 2005, 23, 619-629.	0.8	810
7	Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO). International Journal of Radiation Oncology Biology Physics, 2009, 74, 987-1001.	0.4	797
8	Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2001, 19, 1539-1569.	0.8	742
9	Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. Cmaj, 2004, 170, 1795-1801.	0.9	726
10	Randomized Trial of Breast Irradiation Schedules After Lumpectomy for Women With Lymph Node-Negative Breast Cancer. Journal of the National Cancer Institute, 2002, 94, 1143-1150.	3.0	566
11	Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. International Journal of Radiation Oncology Biology Physics, 2003, 55, 594-605.	0.4	536
12	Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis. Journal of Clinical Oncology, 2000, 18, 1220-1229.	0.8	478
13	Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Practical Radiation Oncology, 2018, 8, 145-152.	1.1	431
14	Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia. Journal of Clinical Oncology, 2007, 25, 1027-1032.	0.8	392
15	Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. Journal of Clinical Oncology, 2013, 31, 4038-4045.	0.8	361
16	Effect of a Decision Aid on Knowledge and Treatment Decision Making for Breast Cancer Surgery. JAMA - Journal of the American Medical Association, 2004, 292, 435.	3.8	358
17	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	13.9	349
18	Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2437-2443.	0.8	331

#	Article	IF	CITATIONS
19	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. International Journal of Radiation Oncology Biology Physics, 2005, 63, 37-46.	0.4	321
20	Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. Journal of Clinical Oncology, 2005, 23, 1-4.	0.8	321
21	External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet, The, 2019, 394, 2165-2172.	6.3	279
22	Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. Journal of Clinical Oncology, 2005, 23, 6931-6940.	0.8	227
23	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002. Journal of Clinical Oncology, 2002, 20, 3317-3327.	0.8	213
24	Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: Results from a randomized trial. International Journal of Radiation Oncology Biology Physics, 1994, 30, 11-16.	0.4	207
25	Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference. Journal of Clinical Oncology, 2008, 26, 791-797.	0.8	206
26	Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 581-587.	3.0	205
27	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Journal of Clinical Oncology, 2016, 34, 4431-4442.	0.8	182
28	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment, 2011, 126, 215-220.	1.1	170
29	The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 47-55.	0.4	162
30	The effects of radiation therapy on quality of life of women with breast carcinoma., 2000, 88, 2260-2266.		159
31	Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. Cmaj, 2004, 170, 1263-1273.	0.9	150
32	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2â€"Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Journal of Clinical Oncology, 2015, 33, 1574-1583.	0.8	146
33	The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. , 1997, 80, 1518-1524.		139
34	Are Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2009, 27, 974-985.	0.8	136
35	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical Radiation Oncology, 2016, 6, e219-e234.	1.1	132
36	Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. Journal of Clinical Oncology, 2008, 26, 1956-1964.	0.8	130

#	Article	IF	Citations
37	Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision. Journal of Clinical Oncology, 2004, 22, 4312-4318.	0.8	128
38	Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. Journal of Clinical Oncology, 2015, 33, 2035-2040.	0.8	118
39	Mastectomy or Lumpectomy? Helping Women Make Informed Choices. Journal of Clinical Oncology, 1999, 17, 1727-1727.	0.8	117
40	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. Journal of the National Cancer Institute, 2015, 107, djv006-djv006.	3.0	112
41	Accelerated Partial Breast Irradiation Consensus Statement from the American Society for Radiation Oncology (ASTRO). Journal of the American College of Surgeons, 2009, 209, 269-277.	0.2	108
42	Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases – an evidence-based practice guideline. BMC Cancer, 2004, 4, 71.	1.1	103
43	Job stress and job satisfaction of cancer care workers. Psycho-Oncology, 2005, 14, 61-69.	1.0	103
44	Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Canadian Journal of Surgery, 2006, 49, 251-8.	0.5	89
45	Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. Cmaj, 2004, 170, 983-994.	0.9	88
46	Patients' Preferences for Therapy in Advanced Epithelial Ovarian Cancer: Development, Testing, and Application of a Bedside Decision Instrument. Gynecologic Oncology, 1996, 62, 329-335.	0.6	85
47	Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. Journal of Clinical Oncology, 2011, 29, 3869-3876.	0.8	83
48	American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. Journal of Clinical Oncology, 2003, 21, 2597-2599.	0.8	81
49	Effect of Metformin vs Placebo on Invasive Diseaseâ€"Free Survival in Patients With Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 1963.	3.8	81
50	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Annals of Surgical Oncology, 2017, 24, 38-51.	0.7	80
51	Predictors of Adverse Cosmetic Outcome in the RAPID Trial: An Exploratory Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 91, 968-976.	0.4	76
52	Physician/Patient Decision Aids for Adjuvant Therapy. Journal of Clinical Oncology, 2005, 23, 1627-1630.	0.8	74
53	Clinical Experience Using Hypofractionated Radiation Schedules in Breast Cancer. Seminars in Radiation Oncology, 2008, 18, 257-264.	1.0	7 3
54	Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. Radiotherapy and Oncology, 2016, 121, 414-419.	0.3	68

#	Article	IF	Citations
55	A Population-Based Study of the Fractionation of Postlumpectomy Breast Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 51-57.	0.4	63
56	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute, 2021, 113, 390-399.	3.0	62
57	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Journal of Clinical Oncology, 2020, 38, 1875-1886.	0.8	59
58	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1ZO3). Breast Cancer Research and Treatment, 2018, 169, 537-548.	1.1	58
59	Regional Nodal Irradiation in Early-Stage Breast Cancer. New England Journal of Medicine, 2015, 373, 1877-1880.	13.9	55
60	A Clinical Trial of Breast Radiation Therapy Versus Breast and Regional Radiation Therapy in Early-Stage Breast Cancer: The MA20 Trial. Clinical Breast Cancer, 2003, 4, 361-363.	1.1	51
61	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	3.4	51
62	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Research and Treatment, 2015, 149, 439-448.	1.1	50
63	Adjuvant Chemotherapy for Breast Cancer — 30 Years Later. New England Journal of Medicine, 2006, 355, 1920-1922.	13.9	43
64	Women's perceptions of their treatment decision-making about breast cancer treatment. Patient Education and Counseling, 2008, 73, 431-436.	1.0	39
65	Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 165-173.	0.4	38
66	Accuracy of ultrasound in localization of breast boost field. Radiotherapy and Oncology, 2004, 72, 61-66.	0.3	37
67	More Evidence That Locoregional Radiation Therapy Improves Survival: What Should We Do?. Journal of the National Cancer Institute, 2005, 97, 82-84.	3.0	37
68	Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 107, 943-948.	0.4	37
69	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919 Journal of Clinical Oncology, 2012, 30, LBA671-LBA671.	0.8	36
70	Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions. Clinical Breast Cancer, 2008, 8, 411-417.	1.1	35
71	Interim Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation (APBI) Using 3D Conformal External Beam Radiation Therapy (3D CRT). International Journal of Radiation Oncology Biology Physics, 2013, 85, 21-22.	0.4	35
72	Abstract GS4-02: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials. Cancer Research, 2019, 79, GS4-02-GS4-02.	0.4	35

#	Article	IF	CITATIONS
73	Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues. Clinical Cancer Research, 2006, 12, 1056s-1060s.	3.2	33
74	Physicianâ€related facilitators and barriers to patient involvement in treatment decision making in early stage breast cancer: perspectives of physicians and patients. Health Expectations, 2013, 16, 373-384.	1.1	33
75	Radiotherapy for breast cancer, the TARGIT-A trial. Lancet, The, 2014, 383, 1716-1717.	6.3	32
76	Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer, 2017, 18, 250-254.	1.1	32
77	Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1370-1379.	3.0	31
78	Use of Conventional Radiation Therapy As Part of Breast-Conserving Treatment. Journal of Clinical Oncology, 2005, 23, 1718-1725.	0.8	29
79	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. JAMA Oncology, 2022, 8, 579.	3.4	27
80	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. Journal of the National Cancer Institute, 2021, 113, 192-198.	3.0	24
81	Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. Patient Education and Counseling, 1999, 37, 283-291.	1.0	23
82	Long-term Results of a Randomized Trial of Accelerated Hypofractionated Whole Breast Irradiation Following Breast Conserving Surgery in Women with Node-Negative Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, S28.	0.4	23
83	Are Some Palliative Care Delivery Systems More Effective and Efficient than Others? A Systematic Review of Comparative Studies. Journal of Palliative Care, 1999, 15, 40-47.	0.4	22
84	The cluster-randomized Quality Initiative in Rectal Cancer trial: evaluating a quality-improvement strategy in surgery. Cmaj, 2010, 182, 1301-1306.	0.9	22
85	Evaluation of a patient file folder to improve the dissemination of written information materials for cancer patients. Cancer, 1998, 83, 1620-1625.	2.0	21
86	Radiation of the Internal Mammary Nodes: Is There a Benefit?. Journal of Clinical Oncology, 2016, 34, 297-299.	0.8	21
87	The Initial Health Assessment: an intervention to identify the supportive care needs of cancer patients. Supportive Care in Cancer, 2004, 12, 19-24.	1.0	20
88	Evaluation of a specialized oncology nursing supportive care intervention in newly diagnosed breast and colorectal cancer patients following surgery: a cluster randomized trial. Supportive Care in Cancer, 2018, 26, 1533-1541.	1.0	20
89	Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. Journal of Clinical Oncology, 2018, 36, 563-571.	0.8	19
90	The Impact of Specialized Oncology Nursing on Patient Supportive Care Outcomes. Journal of Psychosocial Oncology, 2011, 29, 286-307.	0.6	18

#	Article	lF	CITATIONS
91	Clinical practice guidelines for the care and treatment of breast cancer: breast radiotherapy after breast-conserving surgery (summary of the 2003 update). Cmaj, 2003, 168, 437-9.	0.9	18
92	Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis. Breast Cancer Research and Treatment, 2019, 176, 657-667.	1.1	17
93	Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693) Journal of Clinical Oncology, 2019, 37, TPS602-TPS602.	0.8	17
94	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	2.3	16
95	Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	1.4	15
96	Abstract GS4-03: RAPID: A randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT). Cancer Research, 2019, 79, GS4-03-GS4-03.	0.4	15
97	Women's perceptions of their involvement in treatment decision making for early stage breast cancer. Supportive Care in Cancer, 2013, 21, 1717-1723.	1.0	14
98	Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1360-1369.	3.0	14
99	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. JAMA Oncology, 2021, 7, 1196.	3.4	13
100	Accelerated Partial Breast Irradiation (APBI): Where Are We Now?. Current Breast Cancer Reports, 2020, 12, 275-284.	0.5	12
101	The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery. BMC Surgery, 2008, 8, 4.	0.6	11
102	Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Research and Treatment, 2016, 156, 343-349.	1.1	11
103	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	1.4	11
104	Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome Journal of Clinical Oncology, 2014, 32, 1031-1031.	0.8	11
105	Hypofractionated Breast Irradiation: What's Next?. Journal of Clinical Oncology, 2020, 38, 3245-3247.	0.8	10
106	Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial. Cancer Research, 2019, 79, GS4-07-GS4-07.	0.4	10
107	Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer: Results of the Randomized MRC ASTEC and NCIC CTG EN.5 Trials, A Systematic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2008, 72, S353-S354.	0.4	8
108	Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA Network Open, 2018, 1, e182081.	2.8	8

#	Article	IF	CITATIONS
109	Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, S59.	0.4	7
110	Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study. BMC Medical Research Methodology, 2013, 13, 44.	1.4	6
111	The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. International Journal of Radiation Oncology Biology Physics, 2016, 96, S146.	0.4	6
112	DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS. Breast Cancer Research and Treatment, 2021, 188, 133-139.	1.1	6
113	International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. Radiotherapy and Oncology, 2020, 142, 180-185.	0.3	5
114	A pilot study of stereotactic boost for malignant epidural spinal cord compression: clinical significance and initial dosimetric evaluation. Radiation Oncology, 2020, 15, 267.	1.2	5
115	Cancer Antigen 15-3/Mucin 1â€,Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	1.4	5
116	Abstract S5-08: Late side-effects of breast cancer radiotherapy: Second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials. , 2016, , .		5
117	Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation. Journal of Clinical Oncology, 2020, 38, 2254-2262.	0.8	5
118	Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial. Journal of Clinical Oncology, 2008, 26, 550-550.	0.8	5
119	A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32) Journal of Clinical Oncology, 2011, 29, TPS103-TPS103.	0.8	5
120	53 Initial results of a canadian feasibility study of accelerated partial breast irradiation (APBI) using 3-D conformal radiation therapy (3D CRT). Radiotherapy and Oncology, 2006, 80, S16.	0.3	4
121	Robotic Radiosurgery for the Treatment of 1–3 Brain Metastases: A Pragmatic Application of Cost-Benefit Analysis Using Willingness-To-Pay. Technology in Cancer Research and Treatment, 2013, 12, 517-523.	0.8	4
122	Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer. BMJ Open, 2014, 4, e006531.	0.8	4
123	Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)., 2019,,.		4
124	Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial Journal of Clinical Oncology, 2010, 28, 542-542.	0.8	4
125	The time-varying effect of radiotherapy after breast-conserving surgery for DCIS. Breast Cancer Research and Treatment, 2019, 178, 221-230.	1.1	3

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK) Tj ETQq0 @@rgBT /@verlock 10

8

126

#	Article	IF	CITATIONS
127	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy Journal of Clinical Oncology, 2019, 37, 529-529.	0.8	3
128	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patientâ€reported outcomes substudy. Cancer, 2021, , .	2.0	3
129	Robotic radiosurgery for the treatment of one to three brain metastases: A pragmatic application of cost-benefit analysis using willingness to pay Journal of Clinical Oncology, 2012, 30, 17-17.	0.8	3
130	Abstract P5-12-06: Non-adherence to endocrine therapy is associated with a significant increased risk of local recurrence in women ≥65 years with stage T1N0 breast cancer treated with adjuvant endocrine therapy alone after breast-conserving surgery. Cancer Research, 2020, 80, P5-12-06-P5-12-06.	0.4	3
131	Is ipsilateral breast tumor recurrence an independent predictor of distant disease?. International Journal of Radiation Oncology Biology Physics, 1993, 27, 149-150.	0.4	2
132	99 The effects of radiation therapy on quality of life in women with breast cancer: Results of a randomized trial. International Journal of Radiation Oncology Biology Physics, 1997, 39, 184.	0.4	2
133	In Reply to Berrang etÂal. International Journal of Radiation Oncology Biology Physics, 2013, 87, 633.	0.4	2
134	Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ. JAMA Network Open, 2018, 1, e181102.	2.8	2
135	The role of PET-CT in treatment decision making for women with locally advanced cervical cancer Journal of Clinical Oncology, 2015, 33, 5523-5523.	0.8	2
136	CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC) Journal of Clinical Oncology, 2018, 36, 557-557.	0.8	2
137	Lung SBRT Credentialing in the Canadian LUSTRE Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2018, 102, S235.	0.4	1
138	Clinical benefit according to biologic subtype and extent of disease: Who should not receive radiation?. Breast, 2019, 44, S9.	0.9	1
139	The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer. European Journal of Cancer, 2002, 38, S93.	1.3	1
140	Abstract P1-13-01: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis , 2012, , .		1
141	Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial Journal of Clinical Oncology, 2014, 32, 11019-11019.	0.8	1
142	Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl) Journal of Clinical Oncology, 2014, 32, 542-542.	0.8	1
143	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity Journal of Clinical Oncology, 2014, 32, 36-36.	0.8	1
144	In response to Drs. Yaes and Yu. International Journal of Radiation Oncology Biology Physics, 1995, 32, 552-553.	0.4	0

#	Article	lF	Citations
145	Economic analyses. International Journal of Radiation Oncology Biology Physics, 1997, 38, 907-908.	0.4	0
146	Erratum to "Women's perceptions about treatment decision making for ovarian cancer― Gynecologic Oncology, 2003, 90, 232.	0.6	0
147	Re: Is Less More? Lessons in Radiation Schedules in Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 685-686.	3.0	0
148	In regard to fortin et al., int j radiat oncol biol phys 2003;56:1013–1022. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1317-1318.	0.4	0
149	28 Supportive care service needs of newly diagnosed cancer patients: Results of a population based study. Radiotherapy and Oncology, 2006, 80, S9.	0.3	0
150	The Needs of Newly Diagnosed Cancer Patients: Results of a Large Prospective Survey. International Journal of Radiation Oncology Biology Physics, 2007, 69, S563.	0.4	0
151	An Analysis of the Real Time Radiotherapy Review Process in an International Phase III Study: MA.20. International Journal of Radiation Oncology Biology Physics, 2007, 69, S183.	0.4	0
152	DELTA: A Randomized Trial of Decongestive Lymphatic Therapy for Women with Lymphedema following Treatment for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S53.	0.4	0
153	In Reply to Dr. Beal et al. International Journal of Radiation Oncology Biology Physics, 2010, 76, 638-639.	0.4	0
154	Identifying Risk Factors for Locoregional Recurrence Following Postmastectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, S251.	0.4	0
155	Development of a Patient Decision Aid for Older Women With Stage I Breast Cancer Considering Adjuvant Treatment Postlumpectomy. International Journal of Radiation Oncology Biology Physics, 2012, 84, S221.	0.4	O
156	Cardiac Sparing With Breath-hold Technique: A Dosimetric Evaluation of Benefits in Different Patient Populations. International Journal of Radiation Oncology Biology Physics, 2012, 84, S257.	0.4	0
157	Radiation Therapy Quality of Care Indicators for Invasive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E359-E360.	0.4	0
158	PG 10.02 Evolving standards in breast cancer radiotherapy: who should receive locoregional RT?. Breast, 2015, 24, S19-S20.	0.9	0
159	Ten-Year Results of the Breast Intensity Modulated Radiation Therapy (IMRT) Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, S5.	0.4	0
160	Reply to L.B. Marks et al. Journal of Clinical Oncology, 2017, 35, 1258-1259.	0.8	0
161	Breast Irradiation after Conservative Surgery: Some-More-or None. Breast, 2017, 32, S15.	0.9	0
162	Long-Term Outcomes of Microinvasive Breast Cancer in the Canadian Hypofractionation Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, S56-S57.	0.4	0

#	Article	IF	CITATIONS
163	A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, S116.	0.4	0
164	Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer Journal of Clinical Oncology, 2011, 29, 513-513.	0.8	0
165	P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.21, MA.27 Meta-Analysis, 2011, , .		O
166	P5-15-03: Development of a Patient Decision Aid for Women 70 Years and Older with Stage I, Hormonally Sensitive, Breast Cancer Considering Adjuvant Treatment Post-Lumpectomy, 2011, , .		0
167	P2-12-27: Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer 2011		O
168	Abstract A124: Characterization of claudin-low breast cancers. , 2013, , .		0
169	The Canadian Experience with Hypofractionation. , 2016, , 169-180.		O
170	Abstract ES4-2: Treatment morbidity and quality of life considerations. , 2019, , .		0
171	Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results., 2019,,.		0
172	Abstract P6-16-01: Refined local recurrence risk estimates based on a multigene expression assay combined with clinicopathological features significantly impacts radiotherapy recommendation in patients with low/intermediate risk DCIS treated with breast-conserving surgery. , 2020, , .		0
173	Abstract P2-18-01: Single modality adjuvant therapy with radiation (RT) alone or endocrine therapy (ET) alone in women ≥65 years with early stage, hormone receptor positive breast cancer treated with breast-conserving surgery: A population-based analysis. , 2020, , .		0
174	The Elderly and Breast Cancer Radiotherapy. , 2006, , 291-305.		0